Dr. Reddy's in Australia

Dr. Reddy's Laboratories Australia Pty Ltd, with its head office in Melbourne, is a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd., Switzerland. In recent years we have managed to enter this well-regulated market with quality products, responsible business practices and a professional supply chain practice.

We began our operations in Australia in 2009 and are now strengthening our presence with the launch of new Generics Medicine lines and the introduction of specific OTC Consumer Health range. We view the Generics Market in Australia as an opportunity to establish our position in the local industry.

The Generics Medicine portfolio of products for the Australian market has now expanded and includes

  • Anti-dementia
  • Anti-depressants
  • Anti-emetics
  • Anti-epileptics
  • Anti-fungal
  • Anti-neoplastic
  • Anti-psychotics
  • Anti-thrombotics
  • Cardiovascular
  • Gastro-intestinal
  • Osteoperosis
  • Psychotropic
  • Urological


In 2014 Dr. Reddy's Australia has launched the first in a new range of OTC products targeted towards specific health issues.

  • ScyteraTM(coal tar) Foam 2% - a foam based formulation for the relief of psoriasis symptoms
  • Hayfexo® - relief from the symptoms of Hayfever allergies The OTC range will be expanded in 2015 across other key categories to meet the changing needs of the Australian health consumer.

Dr. Reddy's Australia Attends APP 2014 to great success!

The Australian Pharmacy Professional Conference and Trade Exhibition (APP) is the country's largest pharmacy conference and trade show. It is also the annual national conference of the The Pharmacy Guild of Australia. APP offers attendees a comprehensive four-day educational program, an exciting social program and a trade exhibition showcasing latest products, services and industry innovations.

We at Dr. Reddy's Australia used this opportunity to extend our corporate presence, present our new generic lines and nationally launch the first stage of our new OTC range – ScyteraTM and Hayfexo® .

ScyteraTM - The Hero OTC Product at APP Addressing an Unmet Patient Need

For the first time our organization was a major sponsor at the APP keynote speaker forums. These are held to update pharmacists on key health issues faced by Australians. At APP 2014 we were proud to introduce Dr. Leon Kircik as our keynote speaker. Dr. Kircik spoke on the subject of psoriasis, and his session offered insights to the importance of the delivery system when treating psoriasis.

Psoriasis affects around 500,000 Australians of all ages, and APP 2014 was the perfect platform for us to educate pharmacists about our new product - ScyteraTM (coal tar) Foam 2% - the first foam based psoriasis product in Australia. Pharmacists were made aware of how we have addressed an unmet patient need with this revolutionary product for the relief of psoriasis symptoms.

ScyteraTM and our other OTC lines are available through pharmacies only.